Department of Pediatric Rheumatology, Ankara Etlik City Hospital, Ankara, Turkey.
Clin Rheumatol. 2024 Jan;43(1):387-392. doi: 10.1007/s10067-023-06752-z. Epub 2023 Sep 2.
INTRODUCTION/OBJECTIVES: This study aimed to evaluate the effect of canakinumab on growth parameters in children with familial Mediterranean fever (FMF).
We conducted a retrospective analysis of 946 pediatric FMF patients followed in our center, of whom 37 were treated with canakinumab for at least three doses. Patients were assessed for demographic, clinical, and genetic characteristics. Data of height and weight percentiles and Z scores were recorded before and after canakinumab treatment and compared.
The study group comprised 37 FMF patients with treated canakinumab. The median age (IQR) at diagnosis and canakinumab initiation was 3.0 (2.0-4.3) years and 7.0 (3.6-10.1) years, respectively. The median weight scores and mean body mass index (BMI) values significantly increased after canakinumab treatment. There was no change in height scores following canakinumab treatment.
Canakinumab treatment has improved off body weight and BMI parameters of FMF patients by controlling disease activity and inflammation. Key Points • To our knowledge, few studies in the literature evaluate the growth parameters of canakinumab treatment in FMF children. • Canakinumab treatment has been shown to affect body weight and BMI positively. • Long-term studies are needed for its effects on height.
介绍/目的：本研究旨在评估卡那单抗对家族性地中海热（FMF）患儿生长参数的影响。
我们对在我中心接受治疗的 946 名儿科 FMF 患者进行了回顾性分析，其中 37 名患者至少接受了 3 剂卡那单抗治疗。评估了患者的人口统计学、临床和遗传特征。记录了卡那单抗治疗前后身高和体重百分位数和 Z 评分的数据，并进行了比较。
研究组包括 37 名接受卡那单抗治疗的 FMF 患者。诊断和开始卡那单抗治疗的中位年龄（IQR）分别为 3.0（2.0-4.3）岁和 7.0（3.6-10.1）岁。卡那单抗治疗后，体重评分和平均体重指数（BMI）值中位数显著增加。卡那单抗治疗后身高评分无变化。
通过控制疾病活动和炎症，卡那单抗治疗改善了 FMF 患者的体重和 BMI 参数。关键点：据我们所知，文献中很少有研究评估卡那单抗治疗 FMF 儿童的生长参数。卡那单抗治疗已被证明对体重和 BMI 有积极影响。需要进行长期研究以了解其对身高的影响。
